Opendata, web and dolomites

CAREMIBRAIN SIGNED

A new brain-dedicated Positron Emission Tomography (PET) system to identify β-amyloid biomarker for the early diagnosis of Alzheimer’s disease and other causes of cognitive decline

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CAREMIBRAIN" data sheet

The following table provides information about the project.

Coordinator
GENERAL EQUIPMENT FOR MEDICAL IMAGING SA 

Organization address
address: CALLE JERONIMO DE MONSORIU, NUM. 92 PLANTA BJ, PUERTA IZQ
city: VALENCIA
postcode: 46022
website: www.oncovision.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.caremibrain.com
 Total cost 4˙393˙596 €
 EC max contribution 4˙393˙596 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENERAL EQUIPMENT FOR MEDICAL IMAGING SA ES (VALENCIA) coordinator 4˙393˙596.00

Map

 Project objective

ONCOVISION is a Spanish SME specialised in design, development, production and commercialisation of organ-dedicated PET systems. Our company submits the present business innovation project with the overall objectives of (1) marketing an innovative brain-dedicated PET system to early diagnosis of Alzheimer’s disease (AD) and other causes of cognitive decline based on the detection of amyloid-β biomarker in the brain using three 18F-labelled tracers recently approved by FDA and EMEA (Florbetapir, Florbetaben, and Flutemetamol) for their clinical use, and (2) validating the clinical performance of this new diagnostic medical device. This new brain-dedicated PET system, targeted to Mental Disorder Units and Nuclear Medicine Units of hospitals in Europe, USA and Japan, is unique in the market and offers several advantages compared to the whole-body PET systems, such as higher resolution, three times higher sensibility, a competitive price (up to three times lower), need of smaller hospital facilities, and lower radiotracer dose to the patient that leads to a lesser cost to the healthcare system. Due to these improved characteristics, the new brain-dedicated PET system will allow an early detection of AD and other causes of cognitive decline and to use this business opportunity to ensure profitability and growth of ONCOVISION. A Phase 1 project was previously funded and implemented (Call: H2020-SMEINST-1-2014; Cut-off date: 18th June, 2014; Topic: PHC-12-2014/2015 Clinical research for the validation of biomarkers and/or diagnostic medical devices; Proposal number: 651145). The feasibility study prepared in Phase 1 has verified the technological as well as economic viability of the product and its clinical validation. During Phase 2 the validation of clinical performance of the product will be carried out, to enable commercialisation in Phase 3.

 Deliverables

List of deliverables.
Web site Websites, patent fillings, videos etc. 2019-09-02 10:35:43

Take a look to the deliverables list in detail:  detailed list of CAREMIBRAIN deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Andrea González-Montoro, Filomeno Sánchez, Rosana Martí, Liczandro Hernández, Albert Aguilar, Julio Barberá, Juan V. Catret, Gabriel Cañizares, Pablo Conde, Efthymios Lamprou, Francisco Martos, Sebatián Sánchez, Luis F. Vidal, Jose M. Benlloch, Antonio J. González
Detector block performance based on a monolithic LYSO crystal using a novel signal multiplexing method
published pages: , ISSN: 0168-9002, DOI: 10.1016/j.nima.2017.10.098
Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAREMIBRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAREMIBRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

PNEUMOSIP (2015)

PNEUMOSIP

Read More  

MPIPETrace (2015)

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Read More  

Respiratory-ImmunoDx (2015)

Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-need

Read More